25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

Mineralys Therapeutics, Inc. Common Stock
Buy, Hold or Sell?

Let's analyze Mineralys Therapeutics, Inc. Common Stock together

I guess you are interested in Mineralys Therapeutics, Inc. Common Stock. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Mineralys Therapeutics, Inc. Common Stock. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Mineralys Therapeutics, Inc. Common Stock

I send you an email if I find something interesting about Mineralys Therapeutics, Inc. Common Stock.

1. Quick Overview

1.1. Quick analysis of Mineralys Therapeutics, Inc. Common Stock (30 sec.)










1.2. What can you expect buying and holding a share of Mineralys Therapeutics, Inc. Common Stock? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$4.76
Expected worth in 1 year
$4.21
How sure are you?
16.7%

+ What do you gain per year?

Total Gains per Share
$-0.55
Return On Investment
-4.4%

For what price can you sell your share?

Current Price per Share
$12.49
Expected price per share
$9.51 - $15.25
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Mineralys Therapeutics, Inc. Common Stock (5 min.)




Live pricePrice per Share (EOD)
$12.49

2.2. Growth of Mineralys Therapeutics, Inc. Common Stock (5 min.)




Is Mineralys Therapeutics, Inc. Common Stock growing?

Current yearPrevious yearGrowGrow %
How rich?$236.9m$198.1m$75.8m27.7%

How much money is Mineralys Therapeutics, Inc. Common Stock making?

Current yearPrevious yearGrowGrow %
Making money-$38.3m-$14.1m-$24.1m-63.1%
Net Profit Margin0.0%0.0%--

How much money comes from the company's main activities?

2.3. Financial Health of Mineralys Therapeutics, Inc. Common Stock (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  

3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Mineralys Therapeutics, Inc. Common Stock?

Welcome investor! Mineralys Therapeutics, Inc. Common Stock's management wants to use your money to grow the business. In return you get a share of Mineralys Therapeutics, Inc. Common Stock.

First you should know what it really means to hold a share of Mineralys Therapeutics, Inc. Common Stock. And how you can make/lose money.

Speculation

The Price per Share of Mineralys Therapeutics, Inc. Common Stock is $12.49. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Mineralys Therapeutics, Inc. Common Stock.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Mineralys Therapeutics, Inc. Common Stock, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $4.76. Based on the TTM, the Book Value Change Per Share is $-0.14 per quarter. Based on the YOY, the Book Value Change Per Share is $1.54 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Mineralys Therapeutics, Inc. Common Stock.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-1.13-9.1%-0.77-6.2%-0.28-2.3%-0.40-3.2%-0.40-3.2%
Usd Book Value Change Per Share-1.07-8.6%-0.14-1.1%1.5412.4%0.403.2%0.403.2%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-1.07-8.6%-0.14-1.1%1.5412.4%0.403.2%0.403.2%
Usd Price Per Share12.11-11.33-10.56-7.30-7.30-
Price to Earnings Ratio-2.68--3.93--9.68--4.54--4.54-
Price-to-Total Gains Ratio-11.29--9.49--32.80--19.48--19.48-
Price to Book Ratio2.55-2.07-1.85-1.31-1.31-
Price-to-Total Gains Ratio-11.29--9.49--32.80--19.48--19.48-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share12.49
Number of shares80
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.140.40
Usd Total Gains Per Share-0.140.40
Gains per Quarter (80 shares)-10.9731.71
Gains per Year (80 shares)-43.88126.83
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-44-540127117
20-88-980254244
30-132-1420380371
40-176-1860507498
50-219-2300634625
60-263-2740761752
70-307-3180888879
80-351-362010151006
90-395-406011411133
100-439-450012681260

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.012.00.00.0%0.012.00.00.0%0.012.00.00.0%
Book Value Change Per Share1.03.00.025.0%2.08.02.016.7%2.08.02.016.7%2.08.02.016.7%2.08.02.016.7%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.012.00.0%0.00.012.00.0%0.00.012.00.0%
Total Gains per Share1.03.00.025.0%2.08.02.016.7%2.08.02.016.7%2.08.02.016.7%2.08.02.016.7%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Mineralys Therapeutics, Inc. Common Stock compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---1.073-0.137-87%1.544-169%0.396-371%0.396-371%
Book Value Per Share--4.7565.505-14%3.982+19%2.974+60%2.974+60%
Current Ratio--8.54815.393-44%25.682-67%15.282-44%15.282-44%
Debt To Asset Ratio--0.1170.076+54%0.390-70%1.033-89%1.033-89%
Debt To Equity Ratio--0.1320.083+59%0.027+386%0.037+260%0.037+260%
Dividend Per Share----0%-0%-0%-0%
Eps---1.131-0.770-32%-0.282-75%-0.397-65%-0.397-65%
Free Cash Flow Per Share---1.008-0.645-36%-0.313-69%-0.360-64%-0.360-64%
Free Cash Flow To Equity Per Share---1.008-0.062-94%0.702-244%0.389-359%0.389-359%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Market Cap621611063.000+3%603261902.460564020107.365+7%525308628.500+15%363109578.622+66%363109578.622+66%
Net Profit Margin----0%-0%-0%-0%
Operating Margin----0%-0%-0%-0%
Operating Ratio----0%-0%-0%-0%
Pb Ratio2.626+3%2.5462.072+23%1.851+38%1.308+95%1.308+95%
Pe Ratio-2.761-3%-2.677-3.928+47%-9.680+262%-4.536+69%-4.536+69%
Price Per Share12.490+3%12.11011.330+7%10.555+15%7.295+66%7.295+66%
Price To Free Cash Flow Ratio-3.097-3%-3.003-4.973+66%-7.969+165%-4.314+44%-4.314+44%
Price To Total Gains Ratio-11.644-3%-11.290-9.491-16%-32.801+191%-19.481+73%-19.481+73%
Quick Ratio--3.10623.403-87%38.607-92%23.072-87%23.072-87%
Return On Assets---0.210-0.132-37%-0.061-71%-0.227+8%-0.227+8%
Return On Equity---0.238-0.144-39%-0.043-82%-0.062-74%-0.062-74%
Total Gains Per Share---1.073-0.137-87%1.544-169%0.396-371%0.396-371%
Usd Book Value--236932000.000274056500.000-14%198157000.000+20%148055416.667+60%148055416.667+60%
Usd Book Value Change Per Share---1.073-0.137-87%1.544-169%0.396-371%0.396-371%
Usd Book Value Per Share--4.7565.505-14%3.982+19%2.974+60%2.974+60%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---1.131-0.770-32%-0.282-75%-0.397-65%-0.397-65%
Usd Free Cash Flow---50223000.000-32137000.000-36%-15594500.000-69%-17904250.000-64%-17904250.000-64%
Usd Free Cash Flow Per Share---1.008-0.645-36%-0.313-69%-0.360-64%-0.360-64%
Usd Free Cash Flow To Equity Per Share---1.008-0.062-94%0.702-244%0.389-359%0.389-359%
Usd Market Cap621611063.000+3%603261902.460564020107.365+7%525308628.500+15%363109578.622+66%363109578.622+66%
Usd Price Per Share12.490+3%12.11011.330+7%10.555+15%7.295+66%7.295+66%
Usd Profit---56342000.000-38313250.000-32%-14145500.000-75%-19803666.667-65%-19803666.667-65%
Usd Revenue----0%-0%-0%-0%
Usd Total Gains Per Share---1.073-0.137-87%1.544-169%0.396-371%0.396-371%
 EOD+5 -3MRQTTM+3 -27YOY+8 -215Y+9 -2110Y+9 -21

3.3 Fundamental Score

Let's check the fundamental score of Mineralys Therapeutics, Inc. Common Stock based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-2.761
Price to Book Ratio (EOD)Between0-12.626
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than13.106
Current Ratio (MRQ)Greater than18.548
Debt to Asset Ratio (MRQ)Less than10.117
Debt to Equity Ratio (MRQ)Less than10.132
Return on Equity (MRQ)Greater than0.15-0.238
Return on Assets (MRQ)Greater than0.05-0.210
Total4/10 (40.0%)

3.4 Technical Score

Let's check the technical score of Mineralys Therapeutics, Inc. Common Stock based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5046.294
Ma 20Greater thanMa 5013.212
Ma 50Greater thanMa 10013.047
Ma 100Greater thanMa 20012.605
OpenGreater thanClose11.890
Total2/5 (40.0%)

4. In-depth Analysis

4.1 About Mineralys Therapeutics, Inc. Common Stock

Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.

Fundamental data was last updated by Penke on 2024-11-20 22:29:02.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Mineralys Therapeutics, Inc. Common Stock earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Mineralys Therapeutics, Inc. Common Stock to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Mineralys Therapeutics, Inc. Common Stock:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--120.2%+120.2%
TTM--210.7%+210.7%
YOY--219.8%+219.8%
5Y--348.0%+348.0%
10Y--473.2%+473.2%
4.3.1.2. Return on Assets

Shows how efficient Mineralys Therapeutics, Inc. Common Stock is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Mineralys Therapeutics, Inc. Common Stock to the Biotechnology industry mean.
  • -21.0% Return on Assets means that Mineralys Therapeutics, Inc. Common Stock generated $-0.21 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Mineralys Therapeutics, Inc. Common Stock:

  • The MRQ is -21.0%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -13.2%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-21.0%TTM-13.2%-7.8%
TTM-13.2%YOY-6.1%-7.1%
TTM-13.2%5Y-22.7%+9.5%
5Y-22.7%10Y-22.7%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-21.0%-11.0%-10.0%
TTM-13.2%-11.8%-1.4%
YOY-6.1%-11.3%+5.2%
5Y-22.7%-12.6%-10.1%
10Y-22.7%-14.3%-8.4%
4.3.1.3. Return on Equity

Shows how efficient Mineralys Therapeutics, Inc. Common Stock is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Mineralys Therapeutics, Inc. Common Stock to the Biotechnology industry mean.
  • -23.8% Return on Equity means Mineralys Therapeutics, Inc. Common Stock generated $-0.24 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Mineralys Therapeutics, Inc. Common Stock:

  • The MRQ is -23.8%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -14.4%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-23.8%TTM-14.4%-9.4%
TTM-14.4%YOY-4.3%-10.1%
TTM-14.4%5Y-6.2%-8.2%
5Y-6.2%10Y-6.2%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-23.8%-14.1%-9.7%
TTM-14.4%-15.8%+1.4%
YOY-4.3%-13.9%+9.6%
5Y-6.2%-18.5%+12.3%
10Y-6.2%-19.2%+13.0%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Mineralys Therapeutics, Inc. Common Stock.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Mineralys Therapeutics, Inc. Common Stock is operating .

  • Measures how much profit Mineralys Therapeutics, Inc. Common Stock makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Mineralys Therapeutics, Inc. Common Stock to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Mineralys Therapeutics, Inc. Common Stock:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--267.8%+267.8%
TTM--313.4%+313.4%
YOY--224.0%+224.0%
5Y--385.5%+385.5%
10Y--498.7%+498.7%
4.3.2.2. Operating Ratio

Measures how efficient Mineralys Therapeutics, Inc. Common Stock is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Mineralys Therapeutics, Inc. Common Stock:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y-0.000
5Y-10Y-0.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.631-2.631
TTM-3.412-3.412
YOY-3.299-3.299
5Y-4.788-4.788
10Y-6.538-6.538
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Mineralys Therapeutics, Inc. Common Stock.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Mineralys Therapeutics, Inc. Common Stock is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 8.55 means the company has $8.55 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Mineralys Therapeutics, Inc. Common Stock:

  • The MRQ is 8.548. The company is very able to pay all its short-term debts. +2
  • The TTM is 15.393. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ8.548TTM15.393-6.845
TTM15.393YOY25.682-10.289
TTM15.3935Y15.282+0.111
5Y15.28210Y15.2820.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ8.5483.690+4.858
TTM15.3933.875+11.518
YOY25.6824.684+20.998
5Y15.2825.946+9.336
10Y15.2826.274+9.008
4.4.3.2. Quick Ratio

Measures if Mineralys Therapeutics, Inc. Common Stock is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Mineralys Therapeutics, Inc. Common Stock to the Biotechnology industry mean.
  • A Quick Ratio of 3.11 means the company can pay off $3.11 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Mineralys Therapeutics, Inc. Common Stock:

  • The MRQ is 3.106. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 23.403. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ3.106TTM23.403-20.298
TTM23.403YOY38.607-15.203
TTM23.4035Y23.072+0.331
5Y23.07210Y23.0720.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.1063.122-0.016
TTM23.4033.451+19.952
YOY38.6074.498+34.109
5Y23.0725.922+17.150
10Y23.0726.414+16.658
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Mineralys Therapeutics, Inc. Common Stock.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Mineralys Therapeutics, Inc. Common Stock assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Mineralys Therapeutics, Inc. Common Stock to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.12 means that Mineralys Therapeutics, Inc. Common Stock assets are financed with 11.7% credit (debt) and the remaining percentage (100% - 11.7%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Mineralys Therapeutics, Inc. Common Stock:

  • The MRQ is 0.117. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.076. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.117TTM0.076+0.041
TTM0.076YOY0.390-0.315
TTM0.0765Y1.033-0.958
5Y1.03310Y1.0330.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1170.353-0.236
TTM0.0760.350-0.274
YOY0.3900.311+0.079
5Y1.0330.367+0.666
10Y1.0330.382+0.651
4.5.4.2. Debt to Equity Ratio

Measures if Mineralys Therapeutics, Inc. Common Stock is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Mineralys Therapeutics, Inc. Common Stock to the Biotechnology industry mean.
  • A Debt to Equity ratio of 13.2% means that company has $0.13 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Mineralys Therapeutics, Inc. Common Stock:

  • The MRQ is 0.132. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.083. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.132TTM0.083+0.049
TTM0.083YOY0.027+0.056
TTM0.0835Y0.037+0.046
5Y0.03710Y0.0370.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1320.393-0.261
TTM0.0830.435-0.352
YOY0.0270.378-0.351
5Y0.0370.451-0.414
10Y0.0370.493-0.456
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Mineralys Therapeutics, Inc. Common Stock generates.

  • Above 15 is considered overpriced but always compare Mineralys Therapeutics, Inc. Common Stock to the Biotechnology industry mean.
  • A PE ratio of -2.68 means the investor is paying $-2.68 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Mineralys Therapeutics, Inc. Common Stock:

  • The EOD is -2.761. Based on the earnings, the company is expensive. -2
  • The MRQ is -2.677. Based on the earnings, the company is expensive. -2
  • The TTM is -3.928. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-2.761MRQ-2.677-0.084
MRQ-2.677TTM-3.928+1.251
TTM-3.928YOY-9.680+5.752
TTM-3.9285Y-4.536+0.608
5Y-4.53610Y-4.5360.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-2.761-2.126-0.635
MRQ-2.677-2.454-0.223
TTM-3.928-3.147-0.781
YOY-9.680-3.335-6.345
5Y-4.536-6.070+1.534
10Y-4.536-6.597+2.061
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Mineralys Therapeutics, Inc. Common Stock:

  • The EOD is -3.097. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -3.003. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -4.973. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-3.097MRQ-3.003-0.094
MRQ-3.003TTM-4.973+1.970
TTM-4.973YOY-7.969+2.996
TTM-4.9735Y-4.314-0.659
5Y-4.31410Y-4.3140.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-3.097-2.981-0.116
MRQ-3.003-3.363+0.360
TTM-4.973-3.667-1.306
YOY-7.969-4.535-3.434
5Y-4.314-8.343+4.029
10Y-4.314-9.276+4.962
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Mineralys Therapeutics, Inc. Common Stock is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 2.55 means the investor is paying $2.55 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Mineralys Therapeutics, Inc. Common Stock:

  • The EOD is 2.626. Based on the equity, the company is underpriced. +1
  • The MRQ is 2.546. Based on the equity, the company is underpriced. +1
  • The TTM is 2.072. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD2.626MRQ2.546+0.080
MRQ2.546TTM2.072+0.474
TTM2.072YOY1.851+0.221
TTM2.0725Y1.308+0.764
5Y1.30810Y1.3080.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD2.6261.863+0.763
MRQ2.5462.028+0.518
TTM2.0722.339-0.267
YOY1.8512.391-0.540
5Y1.3083.666-2.358
10Y1.3084.360-3.052
4.6.2. Total Gains per Share

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Mineralys Therapeutics, Inc. Common Stock.

4.8.3. Insider Transactions

Insiders are holding 2.602% of the shares of Mineralys Therapeutics, Inc. Common Stock.

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-11-06David Malcom RodmanSELL2548215.03
2024-10-11Adam Scott LevySELL1075713.57
2024-10-11Jon CongletonSELL1527113.52
2024-07-24Brian Taylor SlingsbySELL55000013.05
2024-07-16David Malcom RodmanSELL52515
2024-07-11Adam Scott LevySELL1075713.14
2024-07-11Jon CongletonSELL1574613.34
2024-06-14Jon CongletonSELL1622912.52
2024-06-12Jon CongletonSELL1660712.77
2024-06-11Adam Scott LevySELL9681512.94
2024-05-09David Malcom RodmanSELL10015
2024-02-12Samsara Biocapital Gp, LlcBUY55555513.5
2023-11-22Jon CongletonBUY42505.97
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Latest Balance Sheet

Balance Sheet of 2024-09-30. Currency in USD. All numbers in thousands.

Summary
Total Assets268,253
Total Liabilities31,321
Total Stockholder Equity236,932
 As reported
Total Liabilities 31,321
Total Stockholder Equity+ 236,932
Total Assets = 268,253

Assets

Total Assets268,253
Total Current Assets267,732
Long-term Assets521
Total Current Assets
Cash And Cash Equivalents 97,274
Other Current Assets 170,458
Total Current Assets  (as reported)267,732
Total Current Assets  (calculated)267,732
+/-0
Long-term Assets
Property Plant Equipment 69
Long-term Assets Other 452
Long-term Assets  (as reported)521
Long-term Assets  (calculated)521
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities31,321
Long-term Liabilities0
Total Stockholder Equity236,932
Total Current Liabilities
Accounts payable 3,106
Other Current Liabilities 28,215
Total Current Liabilities  (as reported)31,321
Total Current Liabilities  (calculated)31,321
+/-0
Long-term Liabilities
Long-term Liabilities  (as reported)0
Long-term Liabilities  (calculated)0
+/-0
Total Stockholder Equity
Common Stock5
Retained Earnings -253,572
Other Stockholders Equity 490,499
Total Stockholder Equity (as reported)236,932
Total Stockholder Equity (calculated)236,932
+/-0
Other
Cash and Short Term Investments 97,274
Common Stock Shares Outstanding 49,815
Liabilities and Stockholders Equity 268,253
Net Debt -97,274
Net Working Capital 236,411



5.2. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-31
> Total Assets 
11,125
0
0
122,450
114,442
306,435
291,217
277,555
251,636
347,249
318,492
268,253
268,253318,492347,249251,636277,555291,217306,435114,442122,4500011,125
   > Total Current Assets 
11,122
0
0
121,886
110,110
275,274
269,488
265,375
249,103
346,819
318,001
267,732
267,732318,001346,819249,103265,375269,488275,274110,110121,8860011,122
       Cash And Cash Equivalents 
10,612
0
0
48,955
87,701
138,246
101,140
265,890
49,304
90,418
67,856
97,274
97,27467,85690,41849,304265,890101,140138,24687,70148,9550010,612
       Short-term Investments 
0
0
0
71,998
22,409
132,393
159,957
167,461
187,263
248,147
243,259
0
0243,259248,147187,263167,461159,957132,39322,40971,998000
       Other Current Assets 
510
0
0
933
2,701
4,635
8,391
179,075
12,536
8,254
6,886
170,458
170,4586,8868,25412,536179,0758,3914,6352,70193300510
   > Long-term Assets 
3
0
0
564
4,332
31,161
21,729
12,180
2,533
430
491
521
5214914302,53312,18021,72931,1614,332564003
       Property Plant Equipment 
0
0
0
0
0
0
0
0
0
51
42
69
694251000000000
       Long Term Investments 
0
0
0
0
0
31,122
21,678
12,129
2,482
0
0
0
0002,48212,12921,67831,12200000
       Other Assets 
0
0
0
0
0
0
51
0
0
0
0
0
0000051000000
> Total Liabilities 
34,050
0
0
165,864
166,711
10,560
6,207
13,543
10,482
19,204
28,397
31,321
31,32128,39719,20410,48213,5436,20710,560166,711165,8640034,050
   > Total Current Liabilities 
5,054
0
0
7,220
8,067
10,560
6,207
13,543
10,482
19,204
28,397
31,321
31,32128,39719,20410,48213,5436,20710,5608,0677,220005,054
       Accounts payable 
763
0
0
2,563
1,907
2,387
2,196
5,573
601
4,261
1,707
3,106
3,1061,7074,2616015,5732,1962,3871,9072,56300763
       Other Current Liabilities 
4,291
0
0
4,657
6,160
8,173
4,011
2,397
9,881
14,943
26,690
28,215
28,21526,69014,9439,8812,3974,0118,1736,1604,657004,291
   > Long-term Liabilities 
28,996
0
0
158,644
158,644
0
0
0
0
0
0
0
0000000158,644158,6440028,996
       Deferred Long Term Liability 
0
0
0
0
1,631
0
51
0
0
0
0
0
000005101,6310000
> Total Stockholder Equity
-22,925
0
0
-43,414
-52,269
295,875
285,010
264,012
241,154
328,045
290,095
236,932
236,932290,095328,045241,154264,012285,010295,875-52,269-43,41400-22,925
   Common Stock
1
0
0
1
1
4
4
4
4
5
5
5
555444411001
   Retained Earnings -253,572-197,230-156,216-124,708-100,319-77,559-65,418-52,810-43,73700-23,011
   Accumulated Other Comprehensive Income 000-251,636-277,5550-306,435-158,6440000
   Capital Surplus 000000000000
   Treasury Stock000000000000



5.3. Balance Sheets

Currency in USD. All numbers in thousands.




5.4. Cash Flows

Currency in USD. All numbers in thousands.




5.5. Income Statements

Currency in USD. All numbers in thousands.


5.6. Latest Income Statement

Income Statement (annual), 2023-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue0
Cost of Revenue-0
Gross Profit00
 
Operating Income (+$)
Gross Profit0
Operating Expense-84,657
Operating Income-84,657-84,657
 
Operating Expense (+$)
Research Development70,361
Selling General Administrative14,296
Selling And Marketing Expenses14,282
Operating Expense84,65798,939
 
Net Interest Income (+$)
Interest Income10,370
Interest Expense-0
Other Finance Cost-0
Net Interest Income10,370
 
Pretax Income (+$)
Operating Income-84,657
Net Interest Income10,370
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-71,898-97,416
EBIT - interestExpense = -84,825
-72,066
-71,898
Interest Expense0
Earnings Before Interest and Taxes (EBIT)-84,825-71,898
Earnings Before Interest and Taxes (EBITDA)-84,657
 
After tax Income (+$)
Income Before Tax-71,898
Tax Provision-0
Net Income From Continuing Ops-56,582-71,898
Net Income-71,898
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses84,657
Total Other Income/Expenses Net12,759-10,370
 

Technical Analysis of Mineralys Therapeutics, Inc. Common Stock
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Mineralys Therapeutics, Inc. Common Stock. The general trend of Mineralys Therapeutics, Inc. Common Stock is NEUTRAL with 0.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Mineralys Therapeutics, Inc. Common Stock's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (0.0%) Bearish trend (0.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Mineralys Therapeutics, Inc. Common Stock.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 15.00 < 15.12 < 15.25.

The bearish price targets are: 11.26 > 11.10 > 9.51.

Tweet this
Mineralys Therapeutics, Inc. Common Stock Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Mineralys Therapeutics, Inc. Common Stock. The current mas is .

The long score for the Moving Averages is 7/14.
The longshort score for the Moving Averages is 0/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Mineralys Therapeutics, Inc. Common Stock Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Mineralys Therapeutics, Inc. Common Stock. The current macd is -0.32133015.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Mineralys Therapeutics, Inc. Common Stock price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Mineralys Therapeutics, Inc. Common Stock. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Mineralys Therapeutics, Inc. Common Stock price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Mineralys Therapeutics, Inc. Common Stock Daily Moving Average Convergence/Divergence (MACD) ChartMineralys Therapeutics, Inc. Common Stock Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Mineralys Therapeutics, Inc. Common Stock. The current adx is 21.16.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -1/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Mineralys Therapeutics, Inc. Common Stock shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
Mineralys Therapeutics, Inc. Common Stock Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Mineralys Therapeutics, Inc. Common Stock. The current sar is 13.68.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Mineralys Therapeutics, Inc. Common Stock Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Mineralys Therapeutics, Inc. Common Stock. The current rsi is 46.29. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is -2/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending up: The RSI is trending up. +1
Mineralys Therapeutics, Inc. Common Stock Daily Relative Strength Index (RSI) ChartMineralys Therapeutics, Inc. Common Stock Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Mineralys Therapeutics, Inc. Common Stock. The current phase is Continuation in bear market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 2/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Mineralys Therapeutics, Inc. Common Stock price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Mineralys Therapeutics, Inc. Common Stock Daily Stochastic Oscillator ChartMineralys Therapeutics, Inc. Common Stock Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Mineralys Therapeutics, Inc. Common Stock. The current cci is -75.18013159.

Mineralys Therapeutics, Inc. Common Stock Daily Commodity Channel Index (CCI) ChartMineralys Therapeutics, Inc. Common Stock Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Mineralys Therapeutics, Inc. Common Stock. The current cmo is -7.48409078.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Mineralys Therapeutics, Inc. Common Stock Daily Chande Momentum Oscillator (CMO) ChartMineralys Therapeutics, Inc. Common Stock Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Mineralys Therapeutics, Inc. Common Stock. The current willr is -69.87341772.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Mineralys Therapeutics, Inc. Common Stock is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Mineralys Therapeutics, Inc. Common Stock Daily Williams %R ChartMineralys Therapeutics, Inc. Common Stock Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Mineralys Therapeutics, Inc. Common Stock.

Mineralys Therapeutics, Inc. Common Stock Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Mineralys Therapeutics, Inc. Common Stock. The current atr is 0.86745429.

Mineralys Therapeutics, Inc. Common Stock Daily Average True Range (ATR) ChartMineralys Therapeutics, Inc. Common Stock Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Mineralys Therapeutics, Inc. Common Stock. The current obv is 5,125,054.

Mineralys Therapeutics, Inc. Common Stock Daily On-Balance Volume (OBV) ChartMineralys Therapeutics, Inc. Common Stock Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Mineralys Therapeutics, Inc. Common Stock. The current mfi is 39.20.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Mineralys Therapeutics, Inc. Common Stock Daily Money Flow Index (MFI) ChartMineralys Therapeutics, Inc. Common Stock Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Mineralys Therapeutics, Inc. Common Stock.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-07-10STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-07-11STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-07-12ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-07-16STOCH LONG EXITThe %K line crosses below the %D line.
2024-07-17RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-07-19SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-07-22STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-07-23STOCH LONG EXITThe %K line crosses below the %D line.
2024-07-24STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-07-25STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-07-26MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-07-29DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-08-01STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-08-05BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-08-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-12STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-13SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-08-14SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-08-15RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-19ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-08-21CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-08-22MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-08-23SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-08-27DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-08-29STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-30STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-05MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-09-06DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-09-09CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-09-10STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-11STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-09-13DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-09-16STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-09-17STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-09-18STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-09-19STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-09-20STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-09-23MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-09-24DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-25MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-09-27STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-30STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-01SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-10-02BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-10-04ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-10-07RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-10-08MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-10-09STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-10STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-14STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-15WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-10-21RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-10-23MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-10-28STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-30STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-31DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-11-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-06DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-11-07STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-11-11MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-11-12MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-11-13DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-11-19DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-11-21DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-11-22STOCH SHORT EXITThe %K line crosses above the %D line.

6.3. Candlestick Patterns

Mineralys Therapeutics, Inc. Common Stock Daily Candlestick Chart
DateCandlestick Pattern
2024-11-19Bearish Three Line Strike Candle Pattern

6.4. Technical Score

Let's check the technical score of Mineralys Therapeutics, Inc. Common Stock based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5046.294
Ma 20Greater thanMa 5013.212
Ma 50Greater thanMa 10013.047
Ma 100Greater thanMa 20012.605
OpenGreater thanClose11.890
Total2/5 (40.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Mineralys Therapeutics, Inc. Common Stock with someone you think should read this too:
  • Are you bullish or bearish on Mineralys Therapeutics, Inc. Common Stock? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Mineralys Therapeutics, Inc. Common Stock? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Mineralys Therapeutics, Inc. Common Stock

I send you an email if I find something interesting about Mineralys Therapeutics, Inc. Common Stock.


Comments

How you think about this?

Leave a comment

Stay informed about Mineralys Therapeutics, Inc. Common Stock.

Receive notifications about Mineralys Therapeutics, Inc. Common Stock in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.